Leerink notes that CMS released a set of preliminary determinations for the clinical lab fee schedule, including having crosswalked Quanterix’s (QTRX) LucentAD Complete test to a $897 price. While coverage of blood biomarkers remains limited, the firm calls the pricing on CLFS a “meaningful positive” for Quanterix and believes average selling prices could see further upside if the company obtains ADLT status. The firm has a Market Perform rating on Quanterix shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX:
- Quanterix Earnings Call: Strategic Gains Amid Financial Hurdles
- Quanterix downgraded to Hold from Buy at Canaccord
- Quanterix’s Strategic Acquisition and Growth Potential Amidst Challenges
- Quanterix Reports Q2 2025 Financial Results
- Quanterix Hold Rating: Balancing Underperformance with Strategic Opportunities